NSCLC Year in Review Introduction

2020 Year in Review: Non–Small-Cell Lung Cancer —February 6, 2021

Categories:

Lung Cancer

Colleague,

Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums. Adapting to the changes, organizations such as the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and International Association for the Study of Lung Cancer (IASLC) have adopted abbreviated virtual formats for their national and international meetings that delivered cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual format in terms of reach and impact, we are bringing the Year in Review series that seeks to synthesize the presented treatment advances and disseminate the information to clinicians in a timely and effective manner to support cancer care delivery and research.

This edition of Year in Review is focused on non–small-cell lung cancer (NSCLC), which is characterized by a high degree of molecular and genetic heterogeneity that gives rise to different pathways driving tumor evolution and progression as well as mechanisms of treatment response and resistance. In 2020, the US Food and Drug Administration approved 5 novel targeted agents for NSCLC—capmatinib, selpercatinib, pralsetinib, lurbinectedin, and osimertinib. Below is a quick review of some of the topics discussed in this issue, with a focus on key data supporting recent drug approvals, current therapeutic advances, and potentially practice-changing developments in NSCLC.

Increased understanding of the NSCLC genetic landscape has led to identification of new actionable alterations such as MET exon 14 skipping mutations, MET amplifications, and RET fusions for which therapeutic interventions are being developed and actively investigated, as well as novel approaches to EGFR and ALK mutations. Results of the phase 2 GEOMETRY mono-1 study showed that capmatinib, an oral cMET inhibitor, had clinical benefit in patients with MET exon 14–mutated or MET-amplified NSCLC. In addition, capmatinib in combination with the EGFR tyrosine kinase inhibitor (TKI) nazartinib demonstrated clinically relevant efficacy and was well tolerated in patients with EGFR-mutant NSCLC who progressed on EGFR-TKIs.

In the registrational phase 1/2 trial LIBRETTO-001, selpercatinib, an oral RET inhibitor, demonstrated antitumor activity in patients with RET fusion–positive NSCLC and central nervous system metastases, with durable responses in previously treated patients. Another oral RET inhibitor, pralsetinib, was shown to have marked and durable antitumor activity in patients with RET fusion–positive NSCLC based on the results of the phase 1/2 ARROW study.

Osimertinib, an irreversible oral EGFR-TKI that selectively inhibits EGFR-TKI–sensitizing and EGFR T790M–resistance mutations, has shown promising activity in untreated, EGFR-mutated advanced NSCLC. Results of the phase 3 FLAURA trial showed that osimertinib was associated with significantly longer overall survival versus comparator EGFR-TKIs and had a similar safety profile in this patient population. In the phase 3 ADAURA trial, osimertinib was shown to be effective in the adjuvant setting for patients with stage IB to IIIA EGFR mutation–positive NSCLC.

Other important research efforts have yielded findings that support the use of targeted agents in EGFR-mutated NSCLC (afatinib, gefitinib, patritumab deruxtecan), HER2-mutated NSCLC (trastuzumab deruxtecan, poziotinib), and ALK-positive NSCLC (alectinib, lorlatinib, ensartinib).

We are pleased to present the highlights of these topics and more!

David Spigel, MD
Chief Scientific Officer
Director, Lung Cancer Research Program
Principal Investigator
Sarah Cannon Research Institute

Related Articles
Biomarker Testing Is Underutilized Prior to Frontline Testing in Patients with NSCLC
Web Exclusives
Despite guideline recommendations, a retrospective study found inadequate biomarker testing rates to direct targeted therapy.
Review Article Highlights Research Advances in NSCLC Harboring KRAS G12C Mutation
Web Exclusives
Researchers highlighted promising research into early-stage diagnostics and therapies for NSCLC harboring the KRAS G12C mutation discussed in a review article.
Chronic Pneumonitis in Patients with NSCLC Treated with Immune Checkpoint Inhibitor Therapy
Web Exclusives
A recent study found that chronic pneumonitis is a rare complication of immune checkpoint inhibitor therapy in patients with NSCLC.
Last modified: February 10, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code